Vertex Pharmaceuticals Q4 Revenue Seen at $3.16B, EPS $5.15 Estimate
Vertex Pharmaceuticals reported $3.08 billion in Q3 revenue, up 11% year over year, beating EPS estimates while maintaining full-year guidance. For Q4, analysts forecast 8.4% revenue growth to $3.16 billion with $5.15 adjusted EPS, a slowdown from last year’s 15.7% revenue increase.
1. Recent Quarter Performance
In the last quarter, Vertex Pharmaceuticals generated $3.08 billion in revenue, marking an 11% year-over-year increase. The company beat analysts’ EPS estimates and upheld its full-year revenue guidance, highlighting continued strength in its core cystic fibrosis franchise.
2. Q4 Expectations
Analysts project Q4 revenue of $3.16 billion, up 8.4% year over year, and adjusted EPS of $5.15. This forecast represents a notable growth slowdown compared with the 15.7% revenue rise in the same quarter last year, reflecting more moderate sales trends.
3. Peer Comparison and Market Context
Among peers, Biogen’s Q4 revenue fell 7.1% year over year but topped estimates by 3.6%, while Amgen delivered 8.6% revenue growth, beating forecasts by 4.1%. Vertex shares have climbed 1.1% over the past month and carry an average analyst price target of $514.32 versus the current $464.10 share price.